A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization

Bone Marrow Transplantation

Volumn 38, Issue 6, 2006, Pages 407-412

  Kopf, B ^a   De Giorgi, U ^a   Vertogen, B ^a   Monti, G ^a   Molinari, A ^a   Turci, D ^a   Dazzi, C ^a   Leoni, M ^a   Tienghi, A ^a   Cariello, A ^a   Argnani, M ^a   Frassineti, L ^b   Scarpi, E ^b   Rosti, G ^a   Marangolo, M ^a  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; APHERESIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CD34 SELECTION; CELL COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EWING SARCOMA; GERM CELL TUMOR; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASMS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; VINBLASTINE;

EID: 33748436359     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705465     Document Type: Article

References (30)

1. Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R et al. Hematopoietic stem cell transplantation for solid tumors in Europe. Ann Oncol 2004; 15: 653-660.
2. Demirer T, Buckner CD, Bensinger WI. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14: 106-116.
3. De Giorgi U, Rosti G, Zaniboni A, Ballardini M, Minzi MR, Baioni M et al. High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer. Bone Marrow Transplant 2003; 32: 251-255.
4. De Giorgi U, Rosti G, Papiani G, Marangolo M. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients. Haematologica 2002; 87: 95-104.
5. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD 34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
6. Hoeglund M, Smedmyr B, Bengtsson M, Toetterman TH, Yver A, Cour-Chabernaud V et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers - a comparative study. Eur J Haematol 1997; 59: 177-183.
7. Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F et al. Granulocyte-macrophage colony stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-585.
8. Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F et al. Comparative effects of granulocyte-macrophage colony stimulating factor and of granulocyte colony stimulating factor after high-dose cyclofosfamide cancer therapy. J Clin Oncol 1996; 14: 628-635.
9. Dazzi C, Cariello A, Giovanis P, Monti M, Vertogen B, Leoni M et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral stem cell transplantation rescue: A double blind, randomized, placebo-controlled study. Ann Oncol 2003; 14: 559-563.
10. Correale P, Campoccia G, Tsang KY, Micheli L, Cusi MG, Sabatino M et al. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (molgramostim) and hr-IL-2. Results from a phase Ib clinical trial. Eur J Cancer 2001; 37: 892-902.
11. Bengala C, Pazzaglia F, Tibaldi C, Favre C, Vanacore R, Greco F et al. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel and granulocyte colony stimulating factor administered to patients with metastatic breast carcinoma. Cancer 1998; 82: 867-873.
12. Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, De Giorgi U, Carminati O et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: Critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 2003; 32: 489-494.
13. Siegel S, Castellan Jr NJ. Statistica Non Parametrica, 2nd edn. McGraw-Hill: New York, 1992.
14. Armitage P, Berry G. Statistical Methods in Medical Research, 2nd edn. Blackwell Scientific Publications: Cambridge, MA, 1987.
15. SAS Institute Inc. SAS/STAT User's Guide, version 8.02, vol. 1. SAS Institute: Cary, NC, 1989.
16. Seggewiss R, Buss EC, Herrmann D, Goldschmidt H, Ho AD, Fruehauf S. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. Stem Cells 2003; 21: 568-574.
17. Milone G, Leotta S, Indelicato F, Mercurio S, Moschetti G, Di Raimondo F et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: Results depend on degree of previous pretreatment. Bone Marrow Transplant 2003; 31: 747-754.
18. Goterris R, Hernandez-Boluda JC, Teruel A, Gomez C, Lis MJ, Terol MJ et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 2005; 36: 847-853.
19. Andre M, Baudoux E, Bron D, Canon JL, D'Hondt V, Fassotte MF et al. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50-57.
20. Kim S, Kim HJ, Park JS, Lee J, Chi HS, Park CJ et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005; 84: 742-747.
21. Dazzi C, Cariello A, Rosti G, Monti G, Sebastiani L, Argnani M et al. Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumours: E report of 34 cases. Bone Marrow Transplant 1999; 23: 529-532.
22. Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: An intention to mobilize and transplant analysis. Eur J Haematol 2004; 72: 10-17.
23. Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 395-404.
24. Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004; 10: 848-857.
25. Spitzer G, Adkins D, Mathews M, Velasquez W, Bowers C, Dunphy F et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997; 20: 921-930.
26. Yu J, Leisenring W, Bensinger WI, Holmberg LA, Rowley SD. The predictive value of white cell or CD34 + cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999; 39: 442-450.
27. Demirer T, Ilhan O, Ayli M, Arat M, Dagli M, Ozcan M et al. Monitoring of peripheral blood CD34 + cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher 2002; 6: 384-389.
28. Marques JFC, Vigorito AC, Aranha FJP, Lorand-Metz I, Miranda ECM, Lima Filho EC et al. Early total white blood cell recovery is a predictor of low number of apheresis and good CD34+ cell yield. Transfus Sci 2000; 23: 91-100.
29. Steidl U, Fenk R, Bruns I, Neuman F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-36.
30. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180-185.